www.hczq.com 证券研究报告 | 医药生物 | 2026年2月28日 华创医药投资观点&研究专题周周谈 · 第164期 海外CXO 2025财报总结&2026年展望 本周专题联系人：王宏雨 | 华创医药团队： | | | | --- | --- | --- | | 首席分析师郑辰 | 执业编号：S0360520110002 | 邮箱：zhengchen@hcyjs.com | | 联席首席分析师刘浩 | 执业编号：S0360520120002 | 邮箱：liuhao@hcyjs.com | | 医疗器械组组长李婵娟 | 执业编号：S0360520110004 | 邮箱：lichanjuan@hcyjs.com | | 中药和流通组组长高初蕾 | 执业编号：S0360524070002 | 邮箱：gaochulei@hcyjs.com | | 高级分析师王宏雨 | 执业编号：S0360523080006 | 邮箱：wanghongyu@hcyjs.com | | 高级分析师朱珂琛 | 执业编号：S0360524070007 | 邮箱：zhukechen@hcyjs.com | | 分析师陈俊威 | 执 ...

Core Insights - The article discusses IQVIA Holdings Inc.'s recent performance, highlighting a revenue of $4.017 billion in Q2, which was driven by growth in the Technology & Analytics Solutions (TAS) segment [1]. Company Performance - IQVIA reported a revenue of $4.017 billion in Q2, indicating a strong performance compared to previous quarters [1]. - The growth in revenue is primarily attributed to the Technology & Analytics Solutions (TAS) segment, suggesting a focus on innovative solutions within the healthcare sector [1]. Investment Focus - The article emphasizes the importance of innovative companies in the biotech and pharmaceutical sectors, particularly those developing breakthrough therapies with potential acquisition catalysts [1].

Core Insights - The discussion focuses on the performance of the TAS segment, highlighting a 7% growth in constant currency for the fourth quarter [2]. Group 1: Company Performance - The TAS segment experienced a notable growth of 7% in constant currency during the fourth quarter [2]. - Consulting services are emphasized as a key area of focus, particularly in relation to AI initiatives [2].

IQVIA (NYSE:IQV) 2026 Conference February 26, 2026 11:00 AM ET Company ParticipantsMike Fedock - Incoming CFORon Bruehlman - Outgoing CFOConference Call ParticipantsPatrick Donnelly - Managing Director, Tools and Diagnostics/CRO AnalystPatrick DonnellyI think we can look to get started. Thank you, everybody, for joining us, we're here at the Citi MedTech Access Day. I'm Patrick Donnelly, the tools and diagnostics CROs analyst here. Happy to have a unique opportunity here with Ron and Mike, incoming CFO, out ...

Broyhill Asset Management, an investment advisor, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. 2025 witnessed extreme market concentration and a strong focus on artificial intelligence, leaving many sectors behind. The Portfolio, which has been significantly reshaped, now trades at a substantial discount relative to the broader market. The firm strongly believes it will benefit as market fundamentals improve. For the year, the portfolio declined by 1.4%, un ...

Core Viewpoint - ICON Public Limited Company is facing internal scrutiny regarding accounting practices related to revenue recognition, leading to a delay in its financial results for Q4 and full-year 2025 [1][2] Financial Results and Guidance - The company plans to release its delayed financial results on or before April 30, 2026, and has withdrawn its previously issued full-year 2025 financial guidance due to an ongoing investigation by the Audit Committee [2] - Analysts had previously estimated Q4 2025 adjusted EPS to be between $3.27 and $3.32, with revenue expected around $2.00 to $2.01 billion, reflecting modest year-over-year declines [3] - Full-year 2025 consensus estimates for adjusted EPS were in the range of $12.99 to $13.03, with revenue expected between $8.05 and $8.11 billion, down from prior guidance [3] Market Reaction - Following the announcement of the delay and guidance withdrawal, ICON's shares experienced a significant sell-off, dropping approximately 30-40% and reaching multi-year lows in the $70-$90 range [3] Legal Investigations - Multiple law firms have initiated investigations into potential securities law violations, with alerts issued for investors who purchased shares prior to the news [4] Industry Context - ICON operates in the contract research organization (CRO) sector, providing clinical development services to pharmaceutical and biotechnology companies, and competes with firms like IQVIA and Labcorp [4] - The CRO industry relies heavily on accurate revenue recognition for long-term contracts, making the current issues particularly sensitive [4] Financial Metrics - The earnings yield has increased to around 7-8% or higher following the drop in share price, indicating significant uncertainty priced into the market valuation [5] - Trailing P/E ratio is approximately 13-20x, with a price-to-sales ratio around 1.6-1.9x, and enterprise value to sales at approximately 1.3-2.0x [7] - The debt-to-equity ratio stands at 0.38, indicating moderate leverage, while the current ratio is 1.06, suggesting adequate short-term liquidity [7] Future Outlook - The ongoing investigation and delay highlight risks in financial reporting for CROs, with investors awaiting clarity on restated prior periods and updated outlooks for 2025 and 2026 [6]

Core Viewpoint - ICON Public Limited Company (NASDAQ:ICLR) is a significant player in the Contract Research Organization (CRO) sector, providing a wide range of outsourced development services to the pharmaceutical, biotechnology, and medical device industries [1] Financial Performance and Guidance - ICLR's management has reaffirmed its full-year 2025 guidance, expecting revenue between $8.05 billion and $8.1 billion, with adjusted earnings per share (EPS) guidance of $13.00 to $13.20 [3][5] - The stock price of ICLR is currently at $99.70, reflecting a slight increase of 1.29, or 1.31% [4] Market Activity and Stock Performance - ICLR's stock has shown significant volatility over the past year, with a high of $211 and a low of $66.57 [4] - The trading volume for ICLR on the NASDAQ exchange stands at 1,642,937 shares, indicating active investor interest [4] Analyst Insights - Jefferies analyst David Windley has set a price target of $135 for ICLR, suggesting a potential increase of approximately 35.41% from its current price [2][5] - Despite recent challenges, including a significant stock price decline, the optimistic outlook from analysts indicates confidence in the company's recovery [2][5] Legal and Regulatory Issues - Levi & Korsinsky has initiated an investigation into ICLR for potential violations of federal securities laws following a notable decline in stock price that erased billions in shareholder value [2][5]

Have you evaluated the performance of IQVIA Holdings' (IQV) international operations for the quarter ending December 2025? Given the extensive global presence of this clinical testing company, analyzing the patterns in international revenues is crucial for understanding its financial strength and potential for growth.In the modern, closely-knit global economic landscape, the capacity of a business to access foreign markets is often a key determinant of its financial well-being and growth path. Investors no ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-35907 IQVIA HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 27-1341991 (State or other jurisdiction ...

Core Viewpoint - Investors in IQVIA Holdings Inc. should closely monitor the stock due to significant movements in the options market, particularly the high implied volatility of the Feb 20, 2026 $105.00 Call option [1] Company Analysis - IQVIA is currently rated as Zacks Rank 4 (Sell) within the Medical - Instruments Industry, which ranks in the top 34% of the Zacks Industry Rank [3] - Over the past 60 days, no analysts have increased their earnings estimates for the current quarter, while four analysts have revised their estimates downward, leading to a decrease in the Zacks Consensus Estimate from $2.94 per share to $2.87 per share [3] Options Market Insights - The high implied volatility surrounding IQVIA shares suggests that options traders are anticipating a significant price movement, which could indicate an upcoming event that may lead to a substantial rally or sell-off [2][4] - Options traders often seek to capitalize on high implied volatility by selling premium, aiming for the underlying stock to not move as much as initially expected by expiration [4]